Bod Australia recruits Swisse director alongside growing medical cannabis trend

Bod Australia ASX BDA Swisse director George Livery
Swisse is Australia’s top multivitamin brand when measured by sales. The company was purchased by Hong Kong listed, Chinese company Biostime (now H&H Group) in September 2015 for A$1.67 billion.

Cosmetics and natural medicines company Bod Australia (ASX: BDA) has appointed a new executive chairman to spearhead its multifaceted growth spurt in both natural medicines, but also, medical cannabis products.

George Livery will become Bod Australia’s new executive chairman and is expected to take up his new post as of September 1, 2018.

Mr Livery has 28 years’ experience in senior roles domestically and internationally. Most relevant are his last 7 years as director of strategy & corporate at Swisse Wellness Group, a market leading wellness brand.

In addition Mr Livery’s high level executive experience is culminated in positions across multiple other industries including the role of CEO at Village Cinemas Australia, chief operating officer of Village International, commercial director at Hoyts Limited, and director of operations and marketing at the University of Sydney.

His expertise and market experience are expected to accelerate Bod Australia’s strong growth in several sectors, namely as a developer and distributor of cosmetics, natural medicines and health supplements.

In recent years, Bod Australia has developed a significant distribution footprint in the Australian market with access to over 900 pharmacies and is also targeting Asian markets through the daigou market which is experiencing substantial growth rates on the back of Chinese tourism and cross-border e-commerce.

Bod Australia has also built a multi-faceted cannabis business underpinned by a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions.

From natural medicines to medical cannabis

Bod Australia is primarily a developer and distributor of cosmetics and natural medicines, with a significant distribution footprint in the Australian market.

However, the multifaceted natural products developer is keen to build a “sustainable cannabis business” through astute supply and collaboration agreements and to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

Its dynamic move into medical cannabis commercialisation alongside its existing natural medicine products is expected to be spearheaded by the newly-appointed Mr Livery.

“We are delighted to have attracted such a high calibre and well-connected director to chair Bod Australia. George is recognised as an industry leader and has led innovation and change across multiple sectors. He is a Fellow of the Australian Marketing Institute and is seen as an expert in the health and wellness industry,” said Jo Patterson, CEO of Bod Australia.

Ms Patterson also added that Mr Livery’s skills were closely aligned with the company’s current growth strategy with his “unrivalled network and deep understanding of the sector” expected to assist Bod Australia’s sales and revenue growth.

“Bod Australia already has a great stable of evidence-based products that provide a therapeutic outcome. With new SKU’s deep into development in the medicinal cannabis space that will set it apart from other companies and provide another exciting suite of products, Bod Australia will grow into a powerhouse wellness company,” said Mr George Livery.

News of Mr Livery’s appointment helped Bod Australia shares to a gain of around 25% in today’s trading session on the ASX, with shares closing at $0.655 per share.

George is an award-winning market analyst who has authored articles and editorial opinion pieces for multiple publications around the world. He has written about a wide variety of topics including financial markets, stocks, trading, politics and economics.